Fibrinogen and atherothrombosis: Vulnerable plaque or vulnerable patient?;Fibrinogen und atherothrombose: Vulnerable plaque oder vulnerabler patient?

Herz

Volumn 28, Issue 6, 2003, Pages 530-538

  Jaeger, Beate Roxane ^b   Labarrere, Carlos Alberto ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Apheresis; Atherosclerosis; Fibrinogen; Hemotherapy; Thrombosis

Indexed keywords

CHOLESTEROL; FIBRIC ACID DERIVATIVE; FIBRINOGEN;

APHERESIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; BLOOD TRANSFUSION; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FIBRINOLYSIS; FLOW KINETICS; HEART INFARCTION; HEART REINFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; RESTENOSIS; RISK FACTOR; STENT; STROKE; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; BLOOD COMPONENT REMOVAL; CEREBROVASCULAR ACCIDENT; CORONARY RESTENOSIS; FEMALE; FIBRINOGEN; FIBRINOLYTIC AGENTS; HUMANS; MALE; META-ANALYSIS; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; PROSPECTIVE STUDIES; RISK FACTORS; STENTS; SYNDROME; THROMBOSIS;

EID: 0141989664     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-003-2497-5     Document Type: Article

References (52)

1. Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:1368-77.
2. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 2002;106:804-8.
3. Erbel R. Vulnerable Plaque - vulnerables Gefäß - vulnerabler Patient. Rupturgefährdung von Atheromen/Fibroatheromen [Editorial]. Herz 2003;28:483-7.
4. Davidson CJ, Tuddenham EG, McVey JH. 450 million years of hemostasis. J Thromb Haemost 2003;1:1487-94.
5. Physician's Health Study Research Group. Final report on the aspirin component of the ongoing Physician's Health Study. N Engl J Med 1989;321:129-35.
6. Juul-Möller S, Edvardsson N, Jahnmatz B, et al. Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable angina pectoris. Lancet 1992;3540:1421-5.
7. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither in 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
8. Meade TW, North WR, Chakrabati R, et al. Hemostatic function and cardiovascular death: early results of the Northwick Park Heart Study. Lancet 1980;1:1050-4.
9. Meade TW, Mellows S, Brozovic M, et al. Hemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.
10. Thompson SG, Kienast J, Pyke SDM, et al., for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
11. Haines AP, Howarth D, North WRS, et al. Hemostatic variables and outcome of acute new myocardial infarction. Thromb Haemost 1983;50:800-3.
12. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-5.
13. Stone MC, Thorp JM. Plasma fibrinogen - a major coronary risk factor. J R Coll Gen Pract 1985;35:565-9.
14. Kannel WB, D'Agostini RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987;113:1006-10.
15. Thompson SG, Fectrup C, Squire E, et al. Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996;16:357-62.
16. Benderly M, Graff E, Reicher-Seiss H, et al., for the Bezafibrate Infarction Prevention (BIP) Study Group. Fibrinogen is a predictor of mortality in coronary heart disease patients. Arterioscler Thromb Vasc Biol 1996;16:351-6.
17. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:310-8.
18. Heinrich J, Funke H, Rust S, et al. Impact of polymorphis in the alpha- and beta-fibrinogen gene on plasma fibrinogen concentrations of coronary heart disease patients. Thromb Res 1995;77:209-15.
19. Cremer P, Nagel D, Labrot B, et al. Lp(a) as a predictor of myocardial infarction in comparison to fibrinogen, LDL-cholesterol, and other risk factors: the results from the prospective Göttingen Risk Incidence Study (GRIPS). Eur J Clin Invest 1994;24:444-53.
20. Folsom AR. Epidemiology of fibrinogen. Eur Heart J 1995;16:Suppl A:21-4.
21. Little WC. Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction. Am J Cardiol 1990;66:44G-7G.
22. Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol 2000;20:1177-8.
23. Humphries SE, Cook M, Dubowitz M, et al. Role of genetic variation at fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987;1:1452-5.
24. Roy SN, Mukhopadhyay G, Redman CM. Regulation of fibrinogen assembly: transfection of Hep G2 cells with B beta cDNA specifically enhances synthesis of the three component chains of fibrinogen. J Biol Chem 1990;265:6389-93.
25. Dalmon J, Laurent M, Courtois G. The human beta fibrinogen promotor contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol 1993;13:1183-930.
26. Montgomery HE, Clarkson P, Nwose OM, et al. The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the b-fibrinogen gene. Arterioscler Thromb Vasc Biol 1996;16:386-91.
27. Smith EB. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol 1986;15:355-70.
28. Velican D, Velican C. Study of fibrous plaques occurring in the coronary arteries of children. Atherosclerosis 1979;33:201-15.
29. Resch K, Ernst E, Matrai A, et al. Fibrinogen and lipid concentrations as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med 1992;117:371-5.
30. Ernst E. Plasma fibrinogen: an independent cardiovascular risk factor. J Intern Med 1990;227:365-72.
31. Retzinger GS, DeAnglis AP, Patuto SJ. Adsorption of fibrinogen to droplets of hydrophobic phases. Arterioscler Thromb Vasc Biol 1998;18:1948-57.
32. Di Minno G, Mancini M. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arteriosclerosis 1990;10:1-7.
33. Watanabe K, Tanaka K. Influence of fibrin, fibrinogen and fibrinogen degradation products on cultured endothelial cells. Atherosclerosis 1983;48:57-70.
34. Montalescot G, Ankri A, Vicaut E, et al. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 1995;92:31-8.
35. Lowe GD. Fibrinogen and cardiovascular disease: historical introduction. Europ Heart J 1995;16:Suppl:2-5.
36. Shah P, Chander R, Daly K. Plasma fibrinogen level and other risk factor profile: association with coronary artery disease. Br Heart J 1995;71:25.abstract.
37. Yarnell JW, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors of ischemic heart disease. Circulation 1991;83:836-44.
38. Zoccali C, Mallamaci F, Tripepi G, et al. Fibrinogen, mortality, and incident cardiovascular complications in end-stage renal failure. J Intern Med 2003;254:132-9.
39. Qizilbash N, Jones L, Warlow C, et al. Fibrinogen and lipid concentrations as risk factors for transient ischemic attacks and minor ischemic strokes. BMJ 1991;303:605-9.
40. Scarabin P-Y, Bara L, Ricard S, et al. Genetic variation at the b-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction: the ECTIM Study. Arterioscler Thomb 1993;13:886-91.
41. Wilkes HC, Kelleher C, Meade TW. Smoking and plasma fibrinogen. Lancet 1988;1:307-8.
42. Erbel R, Heusch G. Brief review: coronary microembolization. J Am Coll Cardiol 2000;36:22-4.
43. Lorenzot R, Sobel JH, Bini A, et al. Low molecular weight fibrinogen degradation products stimulate the release of growth factors from endothelial cells. Thromb Hemost 1992;68:357-63.
44. Seidel D. Apheresis. In: Kostner GM, Kostner KM, eds. Atherosclerosis: risk factors, diagnosis, and treatment. Monduzzi editore. International Proceedings EAS Salzburg 2002. Florenz: Monduzzi, 2002:609-14.
45. Jaeger BR. The HELP system for the treatment of atherothrombotic disorders: a review. Ther Apher Dial 2003;7:391-6.
46. Jaeger BR, Goehring P, Schirmer J, et al. Consistent lowering of clotting factors for the treatment of acute cardiovascular syndromes and hypercoagulability - a different pathophysiologic approach. Ther Apher Dial 2001;5:252-9.
47. Moriarty PM, Gibson CA, Shih J, et al. C-reactive protein and other markers of inflammation among patients undergoing H.E.L.P. LDL apheresis. Atherosclerosis 2001;158:495-8.
48. Jaeger BR, Tsobanelis T, Bengel F, et al. Long-term prevention of premature coronary atherosclerosis in homozygous familial hypercholesterolemia. J Pediatr 2002;141:125-8.
49. Jaeger BR, Meiser B, Nagel D, et al. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation 1997;96:Suppl II:154-8.
50. Jaeger BR, Oberhoffer M, Kreuzer E, et al. Postoperative lowering of fibrinogen for the prevention of early graft closure after CABG. Atherosclerosis 2002;140:Suppl:157.
51. Jaeger BR, Kreuzer E, Knez A, et al. Case reports on emergency treatment of cardiovascular syndromes through heparin mediated low density lipoprotein/fibrinogen precipitation: a new approach to augment cerebral and myocardial salvage. Ther Apher Dial 2002;6:394-8.
52. Jaeger BR, Seidel D. Hyperlipoproteinämie und LDL-Apherese. Herz 2001;26:531-44.